Novel therapies shaking up the treatment of kidney cancer

The following round table discussion between a panel of doctors (oncologists) discusses the recent advances in how renal cell carcinoma (RCC) is treated. Although treatment options for RCC have improved dramatically over the past decade, oncologists often face difficult decisions in selecting the right course of treatment for the individual patient, such as; which drug(s) […]

read more

EU approves nivolumab for renal cell carcinoma (RCC)

Nivolumab (Opdivo) has received approval for 2 new indications from the European Commission. Nivolumab is an programmed death receptor-1 (PD-1) immune checkpoint inhibitor that activates the immune system’s T cells to detect and attack cancer cells. The drug is already approved in Europe for use in previously treated patients with metastatic squamous non-small-cell lung cancer […]

read more

Cancer immunotherapy: Patient education is critical

In part I of this blog, Debra Madden, a 2-time cancer survivor (Hodgkin’s lymphoma and breast cancer) and Cancer Research Advocate, explains why it is important that patients understand that immunotherapy: Is not for every cancer patient Is not effective for every cancer patient Results in variable responses and variable time to response Requires different […]

read more

Cholesterol pill boosts cancer immunotherapy

Studies in mice suggest that tweaking cholesterol levels with avasimibe, a lipid-lowering drug, may boost the effectiveness of new immunotherapy drugs, such as nivolumab (Opdivo) and pembrolizumab (Keytruda). Adding avasimibe to PD-1 inhibitors improved tumour inhibition and increased survival in mice. Read more here.

read more
Showing 301 to 304 of 304 results